Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Not Yet Recruiting3
Recruiting2
Active Not Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07493291Active Not RecruitingPrimary

Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients

NCT07491055Not Yet Recruiting

Wide-Angle Tomosynthesis and AI in Diagnostic Mammography

NCT07333937Phase 2Not Yet RecruitingPrimary

Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer

NCT06717295RecruitingPrimary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

NCT06820554Not Yet RecruitingPrimary

Thyroid Dysfunction Induced by Radiotherapy Treatment in Patients with Breast Cancer

NCT06621459RecruitingPrimary

Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)

Showing all 6 trials

Research Network

Activity Timeline